Memorial Sloan Kettering

October 2019 Newsletter

Issue link: https://read.uberflip.com/i/1171524

Contents of this Issue

Navigation

Page 1 of 3

In her honor, and in recognition of the wonderful care she received at Memorial Sloan Kettering, he created the Arden Norris and Mary Cecelia Witherwax Foundation. The Foundation now supports sarcoma research and the work of Dr. D'Angelo at MSK. Arden has also established a gift in his will with MSK to further this important research—and Mary's wishes—for many years to come. "Mary was an inspiring woman and her gift will help patients for generations to come," says Dr. D'Angelo. "This type of philanthropic support gives me the opportunity to fully explore options that could potentially impact patients across the globe." In 2019, a lovely ceremony was held to celebrate Mary's memory. Many of the Witherwaxes' loved ones attended, as did Dr. D'Angelo, and even two of Mary's nurses from MSK. Their presence testified to how deeply Mary touched the lives of everyone around her. And through the Witherwaxes' bequest to Memorial Sloan Kettering, Mary can continue to touch lives and help others for a long time to come. Your gift to Memorial Sloan Kettering can honor a loved one or recognize a special caregiver. Contact our Planned Giving office at 800-688-1827 to learn more about your options. Arden Witherwax with his wife's MSK care team, from left, Nurse Heather Ugolini, Dr. Sandra P. D'Angelo, Arden, and Nurse Marlon Lasa-Blandon. RESEARCH UPDATE MSK researchers are leading the charge to uncover new treatment options for metastatic sarcoma. Sarcoma is a potentially deadly group of cancers, making up just one percent of all cancers. Many doctors have never diagnosed or treated the disease. Research underway at MSK includes important findings by medical oncologist Dr. Sandra P. D'Angelo, who is investigating the use of two existing immunotherapy drugs in patients with advanced, inoperable sarcoma. Immunotherapy harnesses the body's own immune system to fight cancer. Patients received the drug nivolumab alone, or in combination with ipilimumab. The combination therapy showed promising results against certain sarcoma subtypes. Further research at MSK will continue to advance knowledge and refine treatment of this rare disease. Gift Honors Mary's Wishes Continued from Page 1 Sandra P. D'Angelo, MD Medical Oncologist PAGE 2

Articles in this issue

view archives of Memorial Sloan Kettering - October 2019 Newsletter